More ANDAs To Be Eligible For Priority Review, Gottlieb Says
Executive Summary
US FDA Commissioner says agency has necessary resources to expand priority review pathway even as multiple review cycles for generic applications remain common.
You may also be interested in...
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.